ClinicalTrials.gg
RecruitingNCT07863557E-typeUpdated Oct 9, 2026

E-Type - Early Wear of Polyethylene Liners Used in DMC

A Phase 4 interventional study of Total Hip Arthroplasty in Osteoarthritis, Osteonecrosis and Dysplasia; Hip, sponsored by Uppsala University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Uppsala University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Osteoarthritis with a site in Sweden — 12 open to participants now, 25 under way, none of them phase 3. Osteoarthritis · Sweden.

Planned enrollment
51st of 57
40 · median 98
Started
2026
with 2 others
Phase 4
5 of 78
1 open now
Primary completion
2033-10
later than 21 of 24 live
Registered
78th of 78
by date
Lead sponsor
3 of 78
Uppsala University

Among the 78 studies in Osteoarthritis with a site in Sweden, this one is the 51st largest by planned enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 4, reaches primary completion later than 21 of the 24 other live ones, and was the 78th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

12 of the 78 studies in Osteoarthritis with a site in Sweden are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Osteoarthritis with a site in Sweden, or all of them as a file.
02

Study summary

This is a single-centre, randomized, double-blinded controlled non-inferiority trial that will be conducted at the Orthopaedic Department at Uppsala University Hospital, Uppsala. The aim of the study is to evaluate the performance of a dual mobility acetabular component with a Vitamin E-infused highly crosslinked polyethylene (VEPE) liner compared to a conventional polyethylene (PE) liner in adult patients with symptomatic osteoarthritis, osteonecrosis, or dysplasia of the hip requiring a hip replacement. The assessments will focus on early wear, cup migration, adverse events, and clinical outcomes. Measurements will be conducted using Computed Tomography Radiostereometric Analysis (CT-RSA) instead of traditional radiostereometric analysis. The study hypothesis is that the PE liner will be non-inferior to the VEPE liner in terms of early wear over a two-year period.

Read the detailed description

Dual-mobility cups (DMCs) were introduced to reduce the risk of dislocation after total hip arthroplasty (THA) by improving stability while maintaining a large range of motion. Concerns remain regarding polyethylene liner wear due to the larger articulating surface, as wear rates exceeding 0.1 mm/year have been associated with osteolysis and aseptic loosening. Vitamin E-infused highly crosslinked polyethylene (VEPE) has been developed to improve wear resistance, and CT-based radiostereometric analysis (CT-RSA) provides a validated method for assessing implant wear and migration.

The BiMobile Dual Mobility System (Waldemar LINK GmbH) is designed to enhance stability and wear resistance through biocompatible materials and self-centering liners. Although clinical evidence specifically for the BiMobile cup is limited, studies of dual-mobility implants have reported low wear, limited migration, high implant survival, and low rates of loosening.

This study aims to evaluate the performance of the BiMobile dual-mobility cup with a VEPE liner compared with a conventional polyethylene (PE) liner. In a single-centre, randomized, double-blinded non-inferiority trial, patients undergoing THA will be followed for up to five years. The primary objective is to compare in vivo liner wear at two years using CT-RSA. Secondary objectives include evaluation of wear at five years, cup migration and fixation, patient satisfaction, adverse events, and patient-reported outcomes.

All participants will receive a BiMobile dual-mobility cup and will be randomized to either a VEPE or conventional PE liner. CT-RSA examinations will be performed postoperatively and at 6 months, 2 years, and 5 years to measure polyethylene wear, cup migration, and radiological signs of loosening. The study will provide important post-market evidence regarding the long-term safety, fixation, and wear characteristics of the BiMobile system and may help determine whether dual-mobility cups can be more widely used in younger and more active patients.

03

Conditions studied

  • Osteoarthritis
  • Osteonecrosis
  • Dysplasia; Hip

Keywords

  • BiMobile Dual Mobility System
  • Total Hip Arthroplasty
  • Vitamin E-infused highly crosslinked polyethylene
  • Computed Tomography-based Radiostereometric Analysis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years
  • Written
  • Eligible for a Total Hip Arthroplasty according to local guidelines and appropriate candidate for a dual mobility concept
  • Diagnosis: Symptomatic osteoarthritis, osteonecrosis, or dysplasia of the hip requiring a hip replacement

Exclusion criteria

Exclusion Criteria:

  • Confirmed dementia or cognitive impairment
  • Unwillingness to give written
  • Age \<18 or >75 years
  • Hip fracture (traumatic or pathological) in need of a Total Hip Arthroplasty
  • Patients who are not deemed suitable for a THA with a Dual Mobility Cup according to local guidelines and routines
  • Comorbidities that are contraindicators for hip replacement surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    VEPE liner

    Participants are randomized to the BiMobile Dual Mobility System with a Vitamin E-infused highly crosslinked polyethylene (VEPE) liner (E-Dur, Waldemar Link GmbH, Hamburg, Germany).

    Device: Total Hip Arthroplasty

  • Experimental
    PE liner

    Participants are randomized to the BiMobile Dual Mobility System with a conventional highly crosslinked polyethylene (PE) liner (Waldemar Link GmbH, Hamburg, Germany).

    Device: Total Hip Arthroplasty

Interventions

  • DeviceTotal Hip Arthroplasty

    All patients will be operated with an anterolateral or posterior approach using a cemented or uncemented cup (BiMobile, Waldemar Link GmbH, Hamburg, Germany).

06

What researchers measure

Primary outcomes

  1. Wear performance

    To compare the in vivo wear performance of a VEPE liner versus a conventional PE liner using CT-RSA in patients undergoing total hip arthroplasty with a dual mobility cup.

    Time frame: Two years postoperatively.

Secondary outcomes

  1. Long-term wear performance

    To evaluate the in vivo wear performance of the VEPE liner versus the conventional PE liner using CT-RSA.

    Time frame: Five years postoperatively.

  2. Cup stability

    To evaluate stability of the cup by measuring degree of migration using CT-RSA.

    Time frame: Two and five years postoperatively.

  3. Harris Hip Score

    Harris Hip Score (HHS), a clinician-completed tool scored from 0 to 100, will be used to evaluate hip function, pain, and mobility after hip replacement.

    Time frame: Two and five years postoperatively.

  4. Hip Disability and Osteoarthritis Outcome Score

    The Hip Disability and Osteoarthritis Outcome Score (HOOS), a 40-item, patient-reported questionnaire, will be used to assess the participant's opinions about their hip symptoms and functional limitations.

    Time frame: Two and five years postoperatively.

  5. Patient Reported Outcome Scores

    The EQ-5D form will be used to evaluate the participant's quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: Two and five years postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2033, 83 months after the start.

Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 83 months is above that.

Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 7, 2026
StartActual
Oct 8, 2026
Primary completionEst.
Oct 1, 2033
CompletionEst.
Oct 1, 2033
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
Uppsala University Hospital is now Recruiting
Oct 9, 2026
Start date
Oct 2, 2026→Oct 8, 2026 (actual)
Oct 9, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    Uppsala University Hospital is now Recruiting
    Start date Oct 2, 2026→Oct 8, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863557
Lead sponsor
Uppsala University
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 8, 2026
Primary completion
Oct 1, 2033 (estimated)
Completion
Oct 1, 2033 (estimated)
Last update
Oct 9, 2026

Study contacts

Anders Brüggemann, MD, PhD
Contact
anders.bruggemann@uu.se
+46 707-498242
Anders Brüggemann, MD, PhD
principal investigator · Department of Surgical Sciences, Uppsala University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion